your trusted partner for heor€¦ · your trusted partner for heor contact:...
TRANSCRIPT
YOUR TRUSTEDPARTNER FOR HEORContact:[email protected]+91 88005 94510
SKYWARDA N A LY T I C S P R I VAT E L I M I T E D
03INTRODUCTION
04SERVICES
0504HEOR SERVICES
NON HEOR SERVICES 06
07
08
PUBLICATIONS
EVENTS
09OUR TEAM
10CONTACT US
CONTENT
INTRODUCTIONWe are a boutique consultancy specialising in data analytics, primarily in the domain of Health Economics and Outcomes Research (HEOR), pricing, and market access. Our in-house team of expert health economists and systematic reviewers deliver high-quality work within the stipulated timelines.
We provide services to pharmaceutical companies as well as support midsize and largeconsultancies globally. Our company was formally incorporated on 31 August 2017 with a vision to provide quality data analytic services. Over a short span of two years, we have cemented our presence as a high-quality service provider serving clients across Australia, Singapore, India, UAE, UK and USA.
03
Our Clients
Our Offices
San Diego
New YorkLondon
Dubai
MumbaiGurgaon
Dhekiajuli
Sydney
Singapore
SERVICES | HEOR
HTA Submission
We provide support at different steps of an health technology assessment (HTA) submission such as developing a de novo model in Excel, conducting sensitivity analysis, assisting with writing economic sections of the value dossier or preparing references in EndNote™. We also provide independent review services for a model developed externally to minimise the risk of errors.
Model Adaptations
We conduct model adaptations to suit local country requirements based on their local epidemiological, clinical and treatment settings. Our team works in close collaboration with the country and global offices to ensure that the adapted model is suitable for decision making in the country of its implementation.
Technical Reviews
We provide independent review of the models developed externally which helps to minimises the risks of technical/formulae errors or methodical errors. We conduct a detailed thorough sheet by sheet check of the models and use our in-house developed checklist to stress test model on various parameters.
04
Early Economic Model
We develop early economic model to evaluate cost-effectiveness of a drug while it is still in the initial stages of clinical trials, usually in the pre or early Phase III stage. It allows for an early engagement and validation with KOLs regarding the pertinence of the modelling approach, enables identification of key value drivers, provides an estimate of the economically justifiable price (EJP) and helps identify data gaps.
0404
SERVICES | HEOR
Budget Impact Model and Value tools
We develop Budget impact models (BIM) to assess the impact on the budget when introducing a new technology/drug. We do a detailed cost analysis which equips the decision maker with robust information for better planning and allocation of resources. It helps them to identify the additional costs/savings at different stages of the disease management pathway.
Literature Reviews
We conduct systematic literature review (SLR) as well as targeted literature review (TLR) to identify relevant evidence for the decision problem. A thorough review of literature is helpful in identifying previous modelling approaches used in the therapeutic area, assessing information on efficacy and safety for the treatments considered, and identifying data on costs and quality of life that may have been published.
Data Extraction
We can assist with data extraction from published studies, HTA websites and grey literature as required in the desired project-specific template. We have extensive experience in conducting such extractions (English language only) and can perform a quality check on the extractions conducted externally.
Miscellaneous Services
We provide support on a host of miscellaneous services that are an integral part of the HEOR project such as development of manuscripts, abstracts and posters. We can formulate questionnaires for interviews with clinicians to inform the development of the model, prepare materials for presentation as well as present at advisory boards, develop slide decks and assist with writing/editing reports.
05
060406
SERVICES | Non HEOR
Dashboard
We develop interactive, user-friendly dashboards in Excel™ to present the background complex information in a synthesised and easy-to-comprehend manner. We lay out models in a transparent and user-friendly manner to optimise communication and decision-making processes.
Automation
Performing routine tasks such as transfer of data, data entry, etc., can be repetitive, boring, and inefficient. Working in close collaboration with your team, our experts can understand your processes and enhance efficiency by automating many mundane everyday tasks, leading to cost savings and a faster output delivery.
Data Extraction
Extraction of information from PDFs, online forms, images, etc., into the desired template to allow further analysis is an integral part of analysing data. We hold expertise in conducting high-quality data extractions with an independent review to minimise the risk of errors.
Data Analysis
Our experts assist you with in-depth data analysis to generate actionable insights. When it comes to data analysis, we believe in customising the data analysis to your needs and the type of data available. We will work in close collaboration with you to understand your objectives, the data available, and advise you on the type of analysis most suitable for your project.
PUBLICATIONS
• Sharan, N., Rathi, H. (2019). Quality of Life of Individuals with Electromagnetic Hypersensitivity- A Targeted Review of Literature. Value in Health, 22 (SUPPL2), S348
• Sharan, N., Rathi, H. (2019). Efficacy and Safety of Lonafarnib For the Treatment of Progeria- A Qualitative Systematic Review of Literature. Value in Health, 22 (SUPPL2), S335–S336.
• Lynch, K., Aristides, M., Rathi, H., Papadopoulos, G., & McGuire, A. (2018). COST ANALYSIS OF AN INTRANASAL NALOXONE TAKE-HOME PROGRAM: AN AUSTRALIAN CASE STUDY. In DRUG AND ALCOHOL REVIEW, 37(S3), pp. S48-S48).
• Sharan, N., Srivastava, K., Akehurst, R., Erder, H., Strzelczyk, A., Bonthapally, V. (2017). Current Treatment Practices and Their Efficacy and Safety in Refractory Or Super-Refractory Status Epilepticus: A Systematic Review. Value in Health, 20 (5), A189.
• Rathi, H., Pennington, B.,Amadi, A., Lister, S., Nanuwa, K. (2015) The Efficacy and Safety of Abatacept, Adalimumab, Etanercept And Tocilizumab are Comparable In Polyarticular Juvenile Idiopathic Arthritis [abstract]. Value in Health, 18 (7), A636.
• Jain, M., Sonathi, V., Rathi, H., Thomas, S.K., & Mollon, P. (2014) The Economic Impact Of Cardiovascular Events In Patients Post Myocardial Infarction: Uk Health Care Perspective [abstract]. Value in Health, 17 (7), A483-A484.
• Jain, M., Sonathi, V., Rathi, H., Bakuli, A., Thomas, S.K., & Mollon, P. (2014) A DE-NOVO Model to Predict Outcomes of a New Hypothetical Intervention to Reduce CV Risk in Post Mi Patients [abstract]. Value in Health, 17 (7), A558.
• Malcolm, W. A., Leteneux, C., Claxton, L., Taylor, M., & Rathi, H. (2013) The Budget Impact of Introducing Ranibizumab in England and Wales for the Treatment of Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia [abstract]. Value Health, 16 (7), A503.
• Leteneux, C., Claxton, L., Malcolm, W. A., Taylor, M., & Rathi, H. (2013) Cost-Effectiveness of Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia in the United Kingdom [abstract]. Value Health, 16 (7), A505.
• Bergvall, N., Rathi, H., Nixon, R. M., Thom, H. H. Z. (2013) Efficacy of Fingolimod in Delaying Confirmed Disability Progression in Patients Failing Prior Treatment: A Markov Model Application to Estimate Time to Disability Health States [abstract]. Value Health, 16 (7), A618.
• Bergvall, N., Rathi, H., Nixon, R. M., Thom, H. H. Z., Alsop, J., Dunsire, L. (2013) Modeling the Impact of Disease Modifying Treatment on Time to Disability Health States in Multiple Sclerosis: An Evaluation of Oral Therapies Through Indirect Comparisons of 6-Month Confirmed Disability Progression [abstract]. Value Health, 16 (7), A619.
• Kaushal, M., Ahuja, A., Sharan, N., Sharma, D., Arora, A. (2012). Economic burden associated with pancreatic cancer in Europe. Value in Health, Vol. 15 (7), A418.
• Thakur, D., Jha, R., Kaur, S., Sharan, N., Kaur, H. (2012). Cost assessment of companion-diagnostics in breast cancer. Value in Health, 15 (7), A416.
We can assist you with developing high quality manuscripts, abstracts and posters.
A selected list of publications from our team members is provided below*.
* Please note that this list also includes publications from our team members at their previous organisations.
07
08
EVENTSFirst Anniversary
ISPOR 2018
GO TEAM!
ISPOR 2019
HTA at NTU,Singapore
New workspace,new vibes!
Education: M.Sc (int) Economics, IIT Kanpur;
Key skills: Patient level simulation, HTA submissions, Economic Modelling, Dashboard and Model adaptations
Key therapeutic areas: Cardiovascular, Pathological Myopia, Multiple Sclerosis, oncology, rheumatoid arthritis and TRD
Email: [email protected]
Managing Director
Hemant Rathi
Additional position:Adjunct Faculty atManipal Academy of Higher Education Education: M. Pharm Pharmacology,
Panjab University
Key skills: Systematic and targeted literature reviews, dossiers, manuscripts, posters and report writing
Key therapeutic areas: Neurology, oncology, psychiatry, rheumatoid arthritis and rare diseases.
Email: [email protected]
Systematic Reviewer
Education: M.Sc Statistics, Delhi University
Key skills: Cost effectiveness (CE) and budget impact models (BIMs), Model adaptations, Literature Reviews and report writing
Key therapeutic areas: Oncology, clostridium difficile infection (CDI), Mental health, Anti microbial resistance and Sjogren's syndome
Email: [email protected]
Health Economist
Education: MBA, NMIMS (GASCE)
Key skills: Recruitment, Operations, Administration and Project Management
Email: [email protected]
Human Resources& Operation Manager
MEET OUR TEAM
Nitya Kalantri Amit Gupta
Neha Sharan
Skyward Analytics Private Limited
CIN: U74999AS2017PTC018132
CoWrks, Tower A, Paras Twin Towers,
Golf Course Road, Sector 54, Gurgaon, Haryana-122 011, India
+91 8800 594 510
www.skywardanalytics.com
CONTACT